ACID INHIBITORY EFFECT OF GRADED DOSES OF LANSOPRAZOLE IN PATIENTS WITH ZOLLINGER-ELLISON SYNDROME

Lansoprazole, a new substituted benzimidazole, is an effective acid pr oton pump inhibitor acting by inhibiting selectively H+/K+ ATPase of t he gastric parietal cell. This study was performed to assess the effec t of successive 30, 60, 90 and 120 mg dosages of lansoprazole in 4 pat ients suffering from Zollinger-Ellison syndrome. The basal gastric aci d output was markedly inhibited in comparison with baseline values (me an maximal reduction : 87 %; extremes: 75-99 %) and was dose-related. Lansoprazole inhibited pepsin output globally with a dose range effect between 30 and 90 mg/day. The treatment induced a rapid relief of cli nical symptoms. No biological abnormality was noted. These data proved that lansoprazole is efficient for treating gastric acid hypersecreti on in patients suffering from ZES.